Strategic communications for life sciences companies seeking investors, partners and growth

Insight

Providing experienced strategic advice informed by backgrounds in pharma, venture capital and corporate strategy.

Strategy

Helping companies define the narratives that support financing, partnering and commercial success.

Impact

Building visibility, credibility and engagement with investors, partners, customers and other key stakeholders.

Insights

Why AI Makes Strategic Communications More Important, Not Less

Savouring the Sweet Smell of Success at BIO-Europe in Cologne

“Scius comes from the Latin word meaning insight, skilled or well informed.”

“We’re a founder-led strategic communications partner that understands the pressures of raising capital, securing partnerships and advancing innovative science because we’ve been part of the teams driving them.”

Katja Stout, Founder and Managing Partner, Scius Communications

Case Studies

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Positioning Concept Life Sciences as a partner of choice from concept to clinic

Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Positioning Concept Life Sciences as a partner of choice from concept to clinic

Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Contact

If you would like to learn more about how we can help you, please contact us: info@sciuscommunications.com

Home

Strategic communications for life sciences companies seeking investors, partners and growth

Insight

Strategy

Impact

Insights

Case Studies

Amphista Therapeutics: Series B Financing

Anocca

BC Platforms

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Igyxos: Raising the profile of a novel infertility treatment

IRBM

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Medicxi

Microbiotica : First patient dosed announcements

MitoRx Case Study: Promoting a published paper

Pneumagen

Positioning Concept Life Sciences as a partner of choice from concept to clinic

TILT Biotherapeutics

Vaccitech

Vaccitech IPO

VaxEquity Strategic Collaboration with AstraZeneca

Amphista Therapeutics: Series B Financing

Anocca

BC Platforms

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Igyxos: Raising the profile of a novel infertility treatment

IRBM

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Medicxi

Microbiotica : First patient dosed announcements

MitoRx Case Study: Promoting a published paper

Pneumagen

Positioning Concept Life Sciences as a partner of choice from concept to clinic

TILT Biotherapeutics

Vaccitech

Vaccitech IPO

VaxEquity Strategic Collaboration with AstraZeneca

Contact